Locations:
SearchArnon Chait, Chief Executive Officer of Cleveland Diagnostics, a Cleveland Clinic Innovations portfolio company, authors this piece on the continuing inequalities in the diagnosis and results of prostate cancer. Dr. Chait shares that the necessity to improve patient access to effective screening techniques is crucial.
While advancements in cancer research and treatment have improved overall survival rates, disparities in time to diagnosis, access to care, and health outcomes continue to pose significant challenges. Prostate cancer, being the second most common cancer diagnosis and cause of cancer death in men, highlights the urgent need to address these disparities.
The complex interplay of biological, environmental, and social factors drives these disparities. It emphasizes the importance of improving patient access to simple, efficient, and specific screening methods as a foundational step in bridging the gaps in prostate cancer outcomes.
The notable disparities in prostate cancer incidence and outcomes, particularly in racial and socioeconomic differences, underscore the need for a multifaceted approach. Despite a lower overall incidence of cancer, prostate cancer mortality rates among Black men are roughly double that of all other races.
Black men diagnosed with prostate cancer also tend to be younger and are more likely to have more advanced cancer at the time of initial biopsy. Overcoming these disparities requires increased awareness and education about prostate cancer risk, addressing social determinants of health, and making screening and treatment more accessible and affordable for all patients.
By turning to simpler, more cost-effective methods that emphasize efficiency and accuracy, we can create screening tools that overcome the limitations of PSA testing while broadening patient access.
About the author
Dr. Arnon Chait is the chief executive officer of Cleveland Diagnostics. An entrepreneur, scientist, and educator, Dr. Chait’s extensive multidisciplinary background spans physics, engineering, and bioscience. As CEO, he applies his vast experience commercializing innovative science to drive Cleveland Diagnostics’ vision of bringing early cancer detection into everyday practice with advanced testing that is more simple, accurate, and cost-effective than current options.
Read the full article by Arnon Chait, CEO of Cleveland Diagnostics, via PharmaPhorum.
